Center-Authored Papers

Filters: Author is Sharman, Jeff P  [Clear All Filters]
Journal Article
Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS et al..  2016.  Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.. Leukemia & lymphoma. :1-10. Abstract
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I et al..  2014.  Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.. The New England journal of medicine. Abstract
Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O'Brien SM, Pagel JM, Poleski MH et al..  2015.  Management of adverse events associated with idelalisib treatment: expert panel opinion.. Leukemia & lymphoma. :1-8. Abstract
Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC et al..  2015.  Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.. Blood. 126(26):2798-2804. Abstract